Judges Scientific (JDG) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
23 Sep, 2026Executive summary
Revenue declined 21% year-over-year in H1 2026, with like-for-like revenue down 13% excluding a non-recurring Geotek coring expedition in 2025.
Adjusted earnings per share fell 72% to 39.0p, driven by high operational leverage and external headwinds, including U.S. research funding uncertainty, offshore wind investment delays, and Chinese tax exemption process disruptions.
Eight businesses achieved growth, mainly in industrial markets such as semiconductors and batteries, while others faced significant short-term profitability declines.
Cost reductions of nearly £2 million were implemented in underperforming businesses, while investment in talent and innovation continued elsewhere.
Order intake momentum improved significantly by late Q3/early H2, with year-to-date order intake nearly at parity with the prior year.
Financial highlights
Total revenue fell to £55.7m from £70.2m, a 21% decrease year-over-year; like-for-like revenue (excluding Geotek coring) declined 13%.
Adjusted operating profit dropped 66% to £4.8m; adjusted pre-tax profit down 75% to £3.2m; adjusted basic EPS at 39.0p.
Cash conversion remained strong at 90%, generating £4.3 million from operations.
Interim dividend increased by 10% to 36.0p per share.
Adjusted net debt increased to £45.3m due to higher working capital needs; gearing increased to 2.1x.
Outlook and guidance
Trading is guided in line with FY 2026 market expectations, with a significant H2 and Q4 revenue weighting.
Execution risk remains due to high-value, timing-sensitive orders and Q4 revenue concentration, but improved order book visibility supports confidence.
Continued headwinds expected in U.S. scientific research funding and delayed Geotek coring expedition until at least 2028.
Early signs of recovery in China as tax exemption processes resolve and delayed orders begin to ship.
Confidence in long-term growth drivers and business model remains high.
Latest events from Judges Scientific
- Revenue fell 21% in H1 2026, but adjusted EPS is on track to meet full-year expectations.JDG
Q2 2026 TU - Revenue up 9.1%, organic orders down 6%, dividend up 10%, 2026 EPS guided at 200–250p.JDG
H2 2025 - 2025 EPS fell short and 2026 guidance is lower amid US and offshore wind market headwinds.JDG
Trading update - Strong revenue and profit growth, but US market headwinds and funding cuts persist.JDG
H1 2025 - FY25 EPS guidance cut due to US headwinds, but order book and cash remain strong.JDG
Trading Update - H1 profits fell, but acquisitions, dividend growth, and H2 outlook improved.JDG
H1 2024 - 2024 earnings guidance lowered as delayed orders impact full-year results despite H2 progress.JDG
Trading Update - Earnings per share for 2024 are now forecast 5–10% below consensus after a subdued H1.JDG
Trading Update - 2024 saw lower revenue and profit but strong cash flow, acquisitions, and dividend growth.JDG
H2 2024